Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease

Dual‐specificity tyrosine phosphorylation‐regulated kinase‐1A (DYRK1A) is known to phosphorylate the microtubule‐associated tau protein. Overexpression is correlated with tau hyperphosphorylation and neurofibrillary tangle (NFT) formation in Alzheimer's disease (AD). This study assessed the potential of SM07883, an oral DYRK1A inhibitor, to inhibit tau hyperphosphorylation, aggregation, NFT formation, and associated phenotypes in mouse models. Exploratory neuroinflammatory effects were also studied.

[1]  J. Attems,et al.  Phosphorylation of different tau sites during progression of Alzheimer’s disease , 2018, Acta Neuropathologica Communications.

[2]  J. Cummings,et al.  Alzheimer's disease drug development pipeline: 2018 , 2018, Alzheimer's & dementia.

[3]  D. Praticò,et al.  Antileukotriene therapy by reducing tau phosphorylation improves synaptic integrity and cognition of P301S transgenic mice , 2018, Aging cell.

[4]  B. Delatour,et al.  DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives , 2018, Scientific Reports.

[5]  C. Martínez-Cué,et al.  Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes , 2017, Neurobiology of Disease.

[6]  T. Dunckley,et al.  Dyrk1 inhibition improves Alzheimer's disease‐like pathology , 2017, Aging cell.

[7]  L. Petrucelli,et al.  An acetylation–phosphorylation switch that regulates tau aggregation propensity and function , 2017, The Journal of Biological Chemistry.

[8]  J. Trojanowski,et al.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges , 2016, Alzheimer's & Dementia.

[9]  David S. Miller,et al.  Tau: From research to clinical development , 2016, Alzheimer's & Dementia.

[10]  L. Bodea,et al.  Tau physiology and pathomechanisms in frontotemporal lobar degeneration , 2016, Journal of neurochemistry.

[11]  A. Alonso,et al.  Abnormal tau induces cognitive impairment through two different mechanisms: synaptic dysfunction and neuronal loss , 2016, Scientific Reports.

[12]  P. Hof,et al.  Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies , 2016, Biomolecules.

[13]  N. Kurabayashi,et al.  DYRK1A overexpression enhances STAT activity and astrogliogenesis in a Down syndrome mouse model , 2015, EMBO reports.

[14]  J. Bazureau,et al.  Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25–35 peptide administration in mice , 2015, European Neuropsychopharmacology.

[15]  M. Clausen,et al.  FDA-approved small-molecule kinase inhibitors. , 2015, Trends in pharmacological sciences.

[16]  R. Xavier,et al.  The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells , 2015, eLife.

[17]  C. Oliveira,et al.  A novel DYRK1A (Dual specificity tyrosine phosphorylation‐regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro , 2015, Journal of neurochemistry.

[18]  J. Gestwicki,et al.  Synthesis, stereochemical analysis, and derivatization of myricanol provide new probes that promote autophagic tau clearance. , 2015, ACS chemical biology.

[19]  Sul-Hee Chung,et al.  Phosphorylation and Inactivation of Glycogen Synthase Kinase 3β (GSK3β) by Dual-specificity Tyrosine Phosphorylation-regulated Kinase 1A (Dyrk1A)* , 2014, The Journal of Biological Chemistry.

[20]  W. Becker,et al.  DYRK1A: a potential drug target for multiple Down syndrome neuropathologies. , 2014, CNS & neurological disorders drug targets.

[21]  Gabriel Gold,et al.  Alzheimer disease therapy—moving from amyloid-β to tau , 2013, Nature Reviews Neurology.

[22]  W. Becker,et al.  Mechanism of dual specificity kinase activity of DYRK1A , 2013, The FEBS journal.

[23]  Michel Goedert,et al.  Tau pathology and neurodegeneration , 2013, The Lancet Neurology.

[24]  Cornelia M. Wilson,et al.  Tau protein kinases: Involvement in Alzheimer's disease , 2013, Ageing Research Reviews.

[25]  S. Hébert,et al.  Hypothermia-induced hyperphosphorylation: a new model to study tau kinase inhibitors , 2012, Scientific Reports.

[26]  J. Kunitomo,et al.  A novel glycogen synthase kinase‐3 inhibitor 2‐methyl‐5‐(3‐{4‐[(S )‐methylsulfinyl]phenyl}‐1‐benzofuran‐5‐yl)‐1,3,4‐oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer’s disease , 2011, Journal of neurochemistry.

[27]  Meaghan Morris,et al.  The Many Faces of Tau , 2011, Neuron.

[28]  K. Chung,et al.  Dyrk1A Positively Stimulates ASK1-JNK Signaling Pathway during Apoptotic Cell Death , 2011, Experimental neurobiology.

[29]  J. Wegiel,et al.  The role of DYRK1A in neurodegenerative diseases , 2011, The FEBS journal.

[30]  C. Beaudry,et al.  High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation , 2010, BMC Genomics.

[31]  S. Nawoschik,et al.  The JNK pathway amplifies and drives subcellular changes in tau phosphorylation , 2009, Neuropharmacology.

[32]  Yi Li,et al.  Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases , 2009, Journal of neurochemistry.

[33]  J. Wegiel,et al.  Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  Hyun-Jeong Cho,et al.  Dual‐specificity tyrosine(Y)‐phosphorylation regulated kinase 1A‐mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer’s disease , 2008, Journal of neurochemistry.

[35]  D. Dias-Santagata,et al.  Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. , 2007, Molecular biology of the cell.

[36]  Hyun-Jeong Cho,et al.  DYRK1A-mediated Hyperphosphorylation of Tau , 2007, Journal of Biological Chemistry.

[37]  I. Grundke‐Iqbal,et al.  Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration , 2007, The European journal of neuroscience.

[38]  N. Plesnila,et al.  An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[39]  I. Ferrer,et al.  Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models , 2005, Neurobiology of Disease.

[40]  K. Chung,et al.  Regulation of the proapoptotic activity of huntingtin interacting protein 1 by Dyrk1 and caspase‐3 in hippocampal neuroprogenitor cells , 2005, Journal of neuroscience research.

[41]  I. Grundke‐Iqbal,et al.  Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease , 2002, FEBS letters.

[42]  J. Hardy,et al.  Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.

[43]  D. Rujescu,et al.  Regulation of Alternative Splicing of Human Tau Exon 10 by Phosphorylation of Splicing Factors , 2001, Molecular and Cellular Neuroscience.

[44]  Philip R. Cohen,et al.  The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. , 2001, The Biochemical journal.

[45]  K. Titani,et al.  Proline-directed and Non-proline-directed Phosphorylation of PHF-tau (*) , 1995, The Journal of Biological Chemistry.

[46]  Jürgen Götz,et al.  Amyloid-β and tau complexity — towards improved biomarkers and targeted therapies , 2018, Nature Reviews Neurology.

[47]  Márcio Costa,et al.  Protein Phosphorylation is a Key Mechanism in Alzheimer's Disease. , 2017, Journal of Alzheimer's disease : JAD.

[48]  Fei Liu,et al.  Tau and neurodegenerative disease: the story so far , 2016, Nature Reviews Neurology.

[49]  Hemi Malkki,et al.  Neurodevelopmental disorders: Altered epigenetic regulation in early development associated with schizophrenia , 2016, Nature Reviews Neurology.

[50]  B. Dubois,et al.  A phase II trial of tideglusib in Alzheimer's disease. , 2015, Journal of Alzheimer's disease : JAD.

[51]  R. Xavier,et al.  The kinase DYRK 1 A reciprocally regulates the differentiation of Th 17 and regulatory T cells , 2015 .

[52]  A. Alonso,et al.  Expression of Alzheimer-like pathological human tau induces a behavioral motor and olfactory learning deficit in Drosophila melanogaster. , 2013, Journal of Alzheimer's disease : JAD.

[53]  Vijaya L. Melnick,et al.  Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.